Company ProfilePremium

Celemics, Inc.

Company Profile Analysis

Ticker: 331920.KQ주식회사 셀레믹스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Celemics, Inc. - Company showcase

Year Founded & Workforce

2010

40 Employees

Celemics, Inc. logo

Celemics, Inc. Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Celemics, Inc. Overview

Celemics is a Seoul-based developer and manufacturer of hybridization-capture target enrichment reagents for next-generation sequencing (NGS), built on proprietary molecular-cloning (MSSIC™) and molecular-barcoding (BTSeq™) technology developed by its academic founders. It is one of a small number of companies globally — six, by the company's own IPO-era claim — capable of manufacturing target capture probe kits, and it describes itself as the only such manufacturer in Europe, Asia and the Middle East. Its revenue base remains very small (KRW 5.8 bn in FY2025) and has contracted since a FY2022 peak, with persistent operating losses since listing. In 2026 the company changed controlling shareholder, raised roughly KRW 31 bn through rights issues and convertible bonds, and pivoted toward a royalty-plus-kit model for US clinical oncology testing via a three-year, minimum-USD 7.225M agreement with San Diego CLIA lab Achieve Diagnostics. It is, in effect, a technology-rich but commercially sub-scale reagent maker attempting a clinical-market and M&A-led reset.


What the company does

Celemics designs, manufactures and sells reagents and services used in targeted NGS. Its core product is the target capture (target enrichment) kit: a pool of synthetic DNA/RNA probes that hybridize to selected regions of a genome so that only those regions are sequenced. Targeted sequencing is cheaper and deeper than whole-genome sequencing, and is the workhorse method for clinical cancer panels, hereditary-disease panels, exome sequencing and pathogen surveillance.

The company's technology stack, as described in its IPO materials and subsequent disclosures:

MSSIC™ (Massively Separated and Sequence-Identified Cloning): a high-throughput molecular cloning platform combining nano-optical techniques with NGS to isolate, propagate and sequence-verify very large numbers of DNA molecules at low cost. This is the foundational "DNA materials" technology from which probe pools are produced (Dealsite, 30 Jul 2020; Biospectator, 2020).

Probe design and rebalancing: after a pre-production pilot, Celemics rebalances individual probe concentrations to improve coverage uniformity, including in GC-rich and homologous regions that competitors are said to mask (GenomeWeb, US subsidiary launch; Medical-XPRT product page; Funakoshi distributor brochure).

BTSeq™ (Barcode-Tagged Sequencing): a unique-molecular-identifier (UMI) approach with error-removal algorithms, enabling accurate reads of long fragments (>1 kbp) and detection of rare variants below 1% variant allele frequency — relevant to liquid biopsy and minimal residual disease (Biospectator, 2020; Korea University TLO page).

Bioinformatics: Celemics Analysis Service (CAS), an end-to-end pipeline from FASTQ to annotated variants, and a "Sample-to-Report" offering run with Strand Life Sciences' StrandOmics (India) and the BlueBee cloud platform (Netherlands) (KU TLO page).

Business and revenue model

Revenue streamDescriptionWeightSource
Target capture kits (product)Custom and catalogue enrichment panels, whole exome, accessories (library prep, beads, enzymes)~85% of Q2 2026 revenueButler (DART-derived)
NGS servicesSequencing, bioinformatics, custom assay development, infectious-disease whole-genome sequencing for public agencies~15% of Q2 2026 revenueButler; KU TLO
Licensing / royalty (new from Q4 2026)20% royalty on Achieve Diagnostics' US clinical test net sales using five Celemics panels, plus minimum kit purchasesNot yet reported in revenueMoneyToday, 4 Sep 2026; Hankyung, 1 Sep 2026
SubscriptionNone identified——

Historically the model has been a classic research-use-only (RUO) reagent business: one-off and repeat kit sales to hospitals, reference laboratories, pharmaceutical companies, seed/breeding companies and research institutes (Asia Economy, Aug 2024). The 2026 Achieve agreement introduces the first disclosed volume-linked royalty stream tied to reimbursed US clinical testing.

Value-chain position

Celemics sits in the upstream consumables layer of the NGS value chain: it supplies the enrichment chemistry that sits between sample preparation (DNA extraction, library preparation) and sequencing instruments (dominated by Illumina, with MGI, Thermo Fisher and PacBio as alternatives). Its kits are stated to be compatible with Illumina, Thermo Fisher, Pacific Biosciences and MGI instruments (Medical-XPRT product page), which positions it as an instrument-agnostic second source. Downstream, it partially integrates into services (sequencing and bioinformatics) and, from 2026, into clinical testing economics via royalties.

Customer types and end-markets

Customers named or described in public sources: hospitals, contract testing labs, pharmaceutical companies, seed companies, research institutes (Asia Economy, Aug 2024); the Korea Disease Control and Prevention Agency (KDCA) for 2025–2026 infectious-disease surveillance; National Cancer Center Korea (collaboration); distributors and partners in China (Sangon Biotech; earlier Tsingke via distributor Forcula), India (Imperial Life Science), Japan (Funakoshi) and the US (Achieve Diagnostics; MedCare Partners Health Plan of Texas MOU).

End-markets: oncology (hereditary and somatic), rare/inherited disease (clinical exome), pharmacogenomics, infectious disease and pathogen surveillance, liquid biopsy, immune-repertoire/antibody discovery, agrigenomics/breeding, microbiome and synthetic biology.

Company's own description vs. independent characterization

Company description (paraphrased from 2026 press materials and IR): an NGS specialist operating a platform business built on MSSIC since 2010, applied across medicine, drug development, microbiome, synthetic biology and breeding, and the self-producing target capture kit maker in Europe, Asia and the Middle East; in 2026 it framed its strategy as a "two-track" of strengthening the NGS core while investing in new businesses (VentureSquare, 8 Jun 2026).

Independent characterization: Celemics is a technically credible but commercially sub-scale reagent company. Six years after listing it has never generated an operating profit, its revenue (KRW 5.8 bn in FY2025) is lower than in FY2021, and it missed its IPO-era revenue projections by roughly 90% (Dealsite, 24 Oct 2025). Its only profitable year (FY2024) was driven entirely by a fair-value gain on a minority stake in IMBdx. The 2026 change of control, aggressive equity/CB issuance, an earmarked ~KRW 11.5 bn for acquiring "other companies' securities", and an above-market third-party issue to an entity named C&P point to a balance-sheet and strategic reset whose end-state is not yet disclosed. The Achieve contract is the first commercial evidence that the core technology can be monetized at scale in the US, but it is a minimum commitment from a single counterparty that had no prior NGS testing capability.

Strategy

Stated strategy (themes, paraphrased)

From the company's June 2026 statements: Celemics describes a "two-track" strategy — (1) upgrade and strengthen the core NGS business, and (2) secure new growth engines through strategic investments and new-business entry with synergy to NGS, funded by approximately KRW 11.5 bn of the 2026 proceeds earmarked for acquiring other companies' securities. The company said specific investment plans would be disclosed sequentially (VentureSquare, 8 Jun 2026). From September 2026: the company aims to become a US clinical diagnostics player, initially through Achieve's CLIA lab, and then expand into liquid biopsy, precision oncology and companion diagnostics (Hankyung, 1 Sep 2026). From October 2025: re-pointing overseas expansion from China to the US and India via subsidiaries and branches (Dealsite, 24 Oct 2025).

Strategic initiatives — last 24 months

InitiativeDateDescriptionStatusSource
Achieve Diagnostics license + kit supply31 Aug 2026 – 30 Aug 2029Exclusive US license for five cancer panels; 20% royalty on net test sales; min. USD 4.75M kit purchases + min. USD 2.475M royalties = USD 7.225MEffectiveHankyung; MoneyToday
MCPTX MOU20 Jul 2026Evaluate/implement NGS cancer tests (hereditary, somatic, colorectal, breast, lung) with a Texas Medicare-focused health planNon-binding MOUCB Insights / EIN Presswire
Two-track recapitalizationFeb–Jun 2026~KRW 31 bn raised via rights issues and CBsCompletedVentureSquare
C&P strategic issueJul 2026KRW 10 bn for acquisition of other companies' securitiesApproved; completion unconfirmedBullstory; Littlebit
CancerMaster commercialization2,026524-gene CGP panel, Illumina-compatible, priced at 1/3–1/4 of competitorsMarketing phaseSat Economy
KDCA infectious-disease surveillance2025–2026National WGS surveillance supportActiveKU TLO
India expansion2023–Subsidiary + Imperial Life Science distributionActiveKU TLO
US RUO reagent seeding2,025Free CeleMag bead samples for validation partners; AMO-MAG cfDNA kit partnershipActiveLinkedIn
National R&D programs2,024Government projects in breeding, biobank and cancer gene panels; 12 national R&D projects in totalOngoingTheVC

Sustainability / ESG commitments: none disclosed. Cost programs with targets: none disclosed. Medium-term financial targets / guidance: no current guidance published. The only quantified targets on record are the IPO-era projections (2020), which were missed by ~90%.

Products & Services

Pricing for all products is quote-based and not publicly disclosed, except for the company's comparative claim on CancerMaster.

Target enrichment panels — oncology

ProductDescription / capabilityTarget customerYearSource
CancerMasterComprehensive genomic profiling panel analysing 524 cancer-related genes in a single test; runs on installed Illumina sequencers; company claims test cost ~1/3 to 1/4 of competing products; Yonsei medical researchers reported high-accuracy detection of actionable variants in solid tumours and some variants missed by the comparatorHospital molecular pathology labs, reference labs, global precision oncologyPublicised 2026Sat Economy, 2026
OncoRisk PanelHereditary cancer risk genesClinical labs; licensed to Achieve Diagnostics (US)In portfolio by 2023; US license 2026BiopharmIQ; Hankyung, Sep 2026
CancerScreen / Cancer Screen 50 PanelSomatic solid-tumour panel (~50 genes)Clinical labs; licensed to Achieve2026 US licenseHankyung; MoneyToday
ctDNA Breast Cancer PanelCirculating tumour DNA panel for breast cancer (liquid biopsy)Clinical labs; licensed to Achieve2,026Hankyung
ctDNA Colorectal Cancer PanelctDNA panel for colorectal cancerClinical labs; licensed to Achieve2,026Hankyung
ctDNA Lung Cancer PanelctDNA panel for lung cancerClinical labs; licensed to Achieve2,026Hankyung
BRCA1/2 PanelHereditary breast/ovarian cancer genesClinical labsShown 2020Biospectator, 2020
Pan-Cancer PanelMulti-tumour somatic panelClinical labsShown 2020Biospectator, 2020
Sarcoma NGS panelSarcoma-focused panelClinical/researchListed 2026KU TLO keywords
MRD kitMinimal residual disease detection (BTSeq-based)Oncology research/clinicalProgram disclosed 2020Daishin, Dec 2020

Target enrichment panels — germline, exome and pharmacogenomics

ProductDescription / capabilityTarget customerSource
Celemics Whole Exome37 Mb panel covering target regions of major commercial WES panels with >98% coverage; optional mitochondrial/intronic spike-ins; supported by CASResearch and clinical genomics labsMedical-XPRT
Clinical Exome Sequencing (CES) PanelDisease-associated exome for rare/hereditary disease diagnosis; flagship product in IndiaHospital genetics labs; India via Imperial Life ScienceKU TLO; Biospectator 2020
PharmacoScreenPharmacogenomic panelClinical labs, pharmaBiopharmIQ; Biospectator 2020
Custom Target Enrichment PanelsCustomer-specified genes/hotspots; detects all four variant classes; detailed QC on standard DNA samples provided at developmentLabs, pharma, diagnostics developersMedical-XPRT; Biospectator 2020

Infectious disease and agrigenomics

Product / serviceDescriptionCustomerSource
Comprehensive Respiratory Virus panelHybrid-capture respiratory pathogen panelPublic health, hospital labsBiopharmIQ
Influenza / COVID-19 WGS serviceWhole-genome sequencing for variant surveillance; H5N1 work promotedKDCA (2025–2026 contract)KU TLO; LinkedIn
Amplicon- and hybrid-based pathogen enrichmentMicrobiology end-to-end NGS offering promoted at ASM Microbe 2025Microbiology labsLinkedIn
Agrigenomics panelsBreeding/seed-company genotypingSeed companies, breeding programsBiopharmIQ; Asia Economy

Platform technologies and research solutions

ProductDescriptionSource
MSSIC™High-throughput, sequence-verified molecular cloning platform underpinning probe manufactureDealsite 2020; Biospectator
BTSeq™UMI-based barcode-tagged sequencing; long-read accuracy >1 kbp; VAF <1% sensitivity; technology supply to China in 2021Biospectator; Dailypharm; KU TLO
True Repertoire™Immune repertoire / antibody discovery acceleration solutionBiospectator, 2020

Modular accessories (reagents)

ProductFunctionSource
Library Preparation KitNGS library constructionSimply Wall St; Dealsite image
Double-stranded cDNA synthesis kitRNA-to-cDNA for captureSimply Wall St
Hybridization EnhancerCapture efficiencySimply Wall St
Clean-up beads; Streptavidin beadsPurification; capture pull-downSimply Wall St
CeleMag (Celemag) beads; CeleNM beadsMagnetic beads; free samples offered to US validation partners in 2025Simply Wall St; LinkedIn
PolymeraseAmplification enzymeSimply Wall St
Kit formats: Target Enrichment Kit / Standard Kit / All-in-one KitConfigurations sold via Japanese distributorFunakoshi brochure
AMO-MAG Cell-Free DNA Isolation Kit (partner product)cfDNA and blood gDNA extraction, introduced with AMO LifescienceLinkedIn

Services

ServiceDescriptionSource
Celemics Analysis Service (CAS)FASTQ-to-report bioinformatics: variant type, VAF, pathogenicityMedical-XPRT
Sample-to-ReportOne-stop sample receipt through clinical report, with StrandOmics (Strand Life Sciences) and BlueBee cloudKU TLO
Sequencing servicesContract sequencing (excluded from the original US subsidiary's scope)GenomeWeb; Simply Wall St
Custom NGS assay development / biopharma servicesPanel design and validation for pharma and diagnostics developersSimply Wall St

Financial Narrative

Basis: K-IFRS consolidated, fiscal years ending 31 December. FY2021–FY2025 headline figures from Dealsite (24 Oct 2025, citing filings) and Butler (DART-derived); FY2025 detail and trailing-twelve-month (TTM) figures from ValueLine (DART-derived, 26.2Q update). Rounded to KRW 0.1 bn; margin calculations by analyst from rounded figures.

Income statement — 5-year

Reference years: FY2019 revenue KRW 5.14 bn (+34.9% YoY), operating loss KRW 5.0 bn; FY2020 revenue KRW 5.3 bn (+2.4%), operating loss KRW 4.9 bn (Daishin IPO reports, Dec 2020 / Jun 2021). FY2025 YoY growth of -14.2% is as reported by Butler on unrounded figures.

Revenue CAGR FY2021–FY2025: approximately -8.0% per year (analyst calculation, KRW 8.1 bn → 5.8 bn).

FY2025 and latest TTM detail

Note: the 2025 consolidated revenue is given as approximately KRW 5.77 bn in the company's Achieve-related statement (Hankyung, 1 Sep 2026), consistent with ValueLine's KRW 5.76 bn.

Derived H1 2026 (analyst calculation; not a reported figure): using TTM to June 2026 minus FY2025 plus H1 2025 (H1 2025: revenue KRW 2.8 bn, operating loss KRW 1.8 bn, net loss KRW 5.1 bn per Dealsite), H1 2026 implies revenue of roughly KRW 2.3 bn (≈ -19% YoY), operating loss of roughly KRW 2.4 bn and net loss of roughly KRW 11.2 bn. The net loss is dominated by fair-value losses on financial assets (IMBdx stake and/or CB-related derivatives). These derived figures should be checked against the half-year report filed 14 Aug 2026.

Balance sheet

Simply Wall St characterized the balance sheet as low-risk (no material debt) as of its late-2025 data, before the 2026 CB issuance.

Commentary — trends, inflections and drivers

Revenue. Revenue rose sharply in FY2021 (+53%) on the back of COVID-era sequencing demand and the July 2021 Tsingke/China contract, peaked at KRW 8.7 bn in FY2022, then fell 24% in FY2023 as pandemic-related work faded and the China channel collapsed. FY2024 was flat; FY2025 fell 14%, and the TTM figure to June 2026 (KRW 5.2 bn) shows continued contraction. The company attributes the stagnation to the pandemic freezing its overseas brand-building immediately after IPO and to the cancellation of a >KRW 10 bn China order, and says it has re-pointed its strategy toward the US and India (Dealsite, 24 Oct 2025). The domestic NGS market is small, so overseas growth is essential by the company's own account.

IPO-target gap. At IPO the company projected KRW 15 bn revenue and operating breakeven within two years, and revenue of KRW 27.9 bn (2022), KRW 46.9 bn (2023) and KRW 69.9 bn (2024), with operating profit reaching KRW 33.4 bn by 2024. Actual FY2024 revenue was under 10% of target; Dealsite computed a 90.4% shortfall for 2024. This is the single most important credibility fact in the dossier.

Gross margin. At roughly 43–50% gross margin, Celemics earns far below the 60%+ typical of scaled reagent franchises, reflecting sub-scale manufacturing overhead (labour of ~KRW 1.5 bn and depreciation in cost of sales against only ~KRW 5–6 bn revenue). Gross margin compressed from ~50% in FY2025 to ~43% TTM as revenue shrank against a fixed cost base.

Operating costs. SG&A including R&D has been stable at roughly KRW 6.0–6.2 bn, with salaries ~KRW 2.2 bn, fees ~KRW 1.0–1.5 bn and R&D ~KRW 1.0–1.1 bn (ValueLine). The FY2024 operating-loss improvement to KRW 1.9 bn appears to have been a one-year cost-control effect that reversed in FY2025 (KRW 3.3 bn loss).

Below-the-line volatility. Net income is dominated by fair-value movements on the IMBdx stake: a gain of roughly KRW 13 bn in FY2024 when IMBdx listed, then losses of KRW 3.5 bn in H1 2025 alone as IMBdx shares fell from KRW 36,000 at listing to ~KRW 10,400 by October 2025 (Dealsite, 27 Oct 2025). TTM financial valuation losses of KRW 6.3 bn and new interest expense of KRW 0.44 bn (CB accretion) drove the TTM net loss to KRW 10.2 bn. The company has said it has no plan to sell the IMBdx stake.

Inflection candidates. (1) Achieve Diagnostics minimum commitments of ~USD 2.4M per year equate to ~57% of FY2025 revenue annually, if performed. (2) KDCA surveillance contract through 2026. (3) India subsidiary scaling. Against these: shrinking base business and rising financial costs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (as reported)ContentsShare of revenuePeriodSource

Target Capture kits

Custom and catalogue hybrid-capture panels, whole exome, accessories

85%

Q2 2026

Butler (DART-derived)

NGS services

Sequencing, bioinformatics (CAS), custom assay development, infectious-disease WGS for KDCA

15%

Q2 2026

Butler (DART-derived)

Revenue by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Total revenue (KRW Bn)

8.18.76.66.75.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityJurisdictionFunctionStatusSource

Celemics, Inc.

Korea

Parent; R&D, manufacturing, sales

Listed

DART

Celemics America / Celemics USA

California, USA (Irvine at launch; Santa Ana in later directory listings)

Kit sales and business development

Active (consolidated)

GenomeWeb; BiopharmIQ; LinkedIn

Celemics India subsidiary

India (city not disclosed)

Sales; CES panel distribution with Imperial Life Science

Established 2023

KU TLO page

IMBdx, Inc.

Korea (KOSDAQ-listed)

Financial investment, ~9.8% stake at 30 Jun 2025 (FVTPL)

Not consolidated

Dealsite, 27 Oct 2025

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

8.18.76.66.75.8

Revenue growth YoY (%)

52.87.4-24.11.5-14.2

Operating income (KRW Bn)

-6.0-5.7-5.8-1.9-3.3

Net income (KRW Bn)

-5.2-4.8-3.912.3-4.0

Operating margin (%)

-74.1-65.5-87.9-28.4-56.9

Net margin (%)

-64.2-55.2-59.1183.6-69.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%) and Per-Share Data

Line itemFY2025 (KRW Bn)TTM to 30 Jun 2026 (KRW Bn)Source

Revenue

5.765.22

ValueLine

Cost of revenue

2.902.98

ValueLine

Gross profit

2.862.23

ValueLine

Gross margin

49.7%42.7%

Analyst calc.

SG&A (incl. R&D)

6.196.11

ValueLine

of which R&D expense

1.031.10

ValueLine

Operating income

-3.32-3.88

ValueLine

EBITDA

-3.60

-9.26 (aggregator figure; appears to include non-operating items — treat with caution)

ValueLine

Net financial result

-0.71-6.45

ValueLine

of which FVTPL valuation losses

-1.04-6.27

ValueLine

Interest expense

0.010.44

ValueLine

Pre-tax income

-4.03-10.16

ValueLine

Income tax

0.000.00

ValueLine

Net income

-4.03-10.16

ValueLine

EPS, basic (KRW)

-494-1,140

ValueLine

EPS, diluted

Not separately disclosed (anti-dilutive)

——

Dividends per share (KRW)

00

StockHub (yield 0.00%)

Financial Analysis

ItemValueDateSource / method

Total equity

≈ KRW 30.4 bn

30 Jun 2026

Derived: market cap KRW 110.0 bn ÷ P/B 3.62 (ValueLine, 15 Oct 2026); consistent with ROE -33.45% on TTM loss

IMBdx stake (FVTPL) carrying value

KRW 14.6 bn → KRW 11.2 bn

31 Dec 2024 → 30 Jun 2025

Dealsite, 27 Oct 2025

Convertible bonds outstanding

≈ KRW 15 bn (derived: KRW 31 bn total raise less ~KRW 4.3 bn and ~KRW 11.6 bn equity)

Mid-2026

Analyst derivation from VentureSquare / Edaily; not confirmed

Net debt

Not computable from sources reviewed; likely net cash post-2026 raises

——

Goodwill and intangibles

Not publicly disclosed (intangible amortization only ~KRW 0.01–0.03 bn p.a. per ValueLine, implying minimal intangibles)

—

ValueLine

Financial Analysis — Operating cash flow FY2021–FY2025

ItemStatus

Operating cash flow FY2021–FY2025

Not publicly disclosed in sources reviewed. Given persistent operating losses of KRW 1.9–6.0 bn and depreciation of only ~KRW 0.6 bn p.a., operating cash flow has almost certainly been negative every year.

Capex

Not publicly disclosed in sources reviewed. Depreciation of ~KRW 0.4 bn (cost of sales) + ~KRW 0.2 bn (SG&A) p.a. suggests a light asset base.

Free cash flow

Not publicly disclosed; inferred negative

Dividends paid

Zero (no dividend history)

Share buybacks (company)

None identified. Insider purchases in 2026 were personal, not company buybacks

Financing inflows

FY2026 YTD: ≈ KRW 31 bn from rights issues and CBs (VentureSquare); KRW 10 bn C&P issue approved but completion not confirmed

Financial Analysis (Annual)

RatioFY2025 / latestSource / method

ROE

-33.45% (TTM)

ValueLine

ROA

Not computable (total assets not disclosed)

—

ROIC

Not computable

—

Debt / equity

≈ 0.5x (≈ KRW 15 bn CB ÷ ≈ KRW 30.4 bn equity; derived, unconfirmed)

Analyst

Net debt / EBITDA

Not meaningful (negative EBITDA)

—

Interest coverage

Not meaningful (negative EBIT)

—

Asset turnover

Not computable

—

Gross margin

49.7% (FY2025); 42.7% (TTM Jun-2026)

ValueLine / analyst

R&D / revenue

17.9% (FY2025); 21.1% (TTM)

ValueLine / analyst

Price / book

3.62x

ValueLine, 15 Oct 2026

Price / sales (TTM)

≈ 21x

Analyst: KRW 110.0 bn ÷ KRW 5.22 bn

Region Overview

RegionChannel / evidenceDirectionSource

Korea

Direct sales to hospitals, labs, research institutes, seed companies; KDCA 2025–2026 contract; National Cancer Center collaboration

Core market; described by company as small and limited

Dealsite; KU TLO

China

2021 KRW 4.5 bn BTSeq contract (Tsingke via Forcula); Sangon Biotech cited as kit/technology partner; >KRW 10 bn order cancelled

Declined after 2021; company has de-emphasized China

Dailypharm; KU TLO; Dealsite

India

Subsidiary established 2023; ~KRW 0.5 bn first-year sales; CES panel via Imperial Life Science; Strand Life Sciences bioinformatics partner

Growing (company names India a priority)

KU TLO; Dealsite

United States

Subsidiary since c. 2013 (Irvine; later Santa Ana); RUO kit sales; Achieve Diagnostics license from 31 Aug 2026; MCPTX MOU July 2026

Expected to become largest growth driver from Q4 2026 if contract performs

GenomeWeb; Hankyung; CB Insights

Japan

Distributor Funakoshi

Not quantified

Funakoshi brochure

Middle East / Europe

MEDLAB Middle East exhibitor since 2017; BlueBee (Netherlands) partner; IPO-era claim of capture-kit customers in Europe/Middle East

Not quantified

Biospectator; KU TLO

Share Price and Market Valuation

MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Quarter-end share price (KRW)

3,0002,9952,71512,62011,970

Quarter-end market cap (KRW Bn)

24.524.522.2103.0117.3

Share Price & Returns

Reference pointPrice (KRW)Source

IPO price (Aug 2020)

20,000

Biospectator

31 Aug 2020 close

26,200

Dealsite

24 Dec 2020

25,500

Daishin

28 Jun 2021

18,150

Daishin

12 Aug 2024 (intraday, limit-up)

5,200

Asia Economy

31 Dec 2025

2,715

ValueLine

52-week low / high

2,535 / 19,840

Google Finance

15 Oct 2026 close

9,640

ValueLine

Valuation Multiples

MultipleCelemicsPeer comparison

Market cap

≈ KRW 110.0 bn

—

P/E

Not meaningful (TTM EPS KRW -1,140; aggregator shows -10.8x)

—

EV/EBITDA

Not meaningful (negative EBITDA)

—

EV/Sales

Not computed (cash and debt not disclosed); P/S ≈ 21x TTM

—

P/B

3.62x—

StockHub peer screen

Valuation in top 16% of Korean medical-device peers (rich)

StockHub, Oct 2026

Capital Markets

ItemStatusSource

Current analyst consensus

None — zero reports in sample

StockHub

Historical coverage

Shinhan Investment initiated Buy, TP KRW 40,000 (Aug 2020); Daishin issued mandatory IPO-manager reports, not rated (2020–2021)

MTN; Daishin

Dividend history / policy

No dividends paid; yield 0.00%

StockHub

Company buyback authorizations

None identified

—

Insider purchases

Co-CEO, executives and Director Lee Sang-seok bought shares in 2026

TheVC

Credit ratings (Moody's / S&P / Fitch / Korean agencies)

None — unrated

—

Debt maturity profile

CB terms (coupon, maturity, put/call, conversion price) not publicly disclosed in sources reviewed. Korean private CBs commonly carry 3–5 year maturities with investor put options after 1–2 years, which would create potential cash calls from 2027–2028; this is a structural observation, not a confirmed term

—

Share Count (millions)

MetricPre-Feb 2026Post-Feb issue (Jun 2026)Oct 2026Potential post-C&P

Shares outstanding (millions)

8.169.8011.1812.10

Analyst Conclusions

Management guidance and consensus

No formal financial guidance has been published; no consensus estimates exist. The only quantified forward commitment is the Achieve minimum: USD 4.75M of kit purchases plus USD 2.475M of royalties (20% of a USD 12.375M minimum net test-sales commitment) over 31 Aug 2026 – 30 Aug 2029, with automatic one-year renewals absent notice 90 days before expiry (MoneyToday; Hankyung). Spread evenly, this implies roughly USD 2.4M (≈ KRW 3.3 bn) per year — about 57% of FY2025 revenue — but contract-year phasing is not disclosed, and minimums may be back-weighted.

Bull case

  1. Achieve converts Celemics into a recurring-revenue story. Minimums alone would lift annual revenue by roughly half; royalties scale with volume, and only ~172 tests per month at USD 2,000 net are needed to hit the minimum net-sales commitment (MoneyToday). Upside if Achieve's affiliated hospital-contracting organization (hundreds of staff) drives volume.

  2. Low-cost CGP has a real market. A 524-gene panel at 1/3–1/4 of competitor pricing on installed Illumina instruments, with peer-reviewed Yonsei data, is a credible wedge for reference labs and emerging markets (India, Middle East).

  3. Balance sheet de-risked. ~KRW 31 bn raised in 2026 against an operating burn of ~KRW 3–4 bn per year provides multi-year runway and capacity for accretive bolt-ons; insiders have been buying.

Bear case

  1. Track record argues for heavy discounting. Revenue has fallen for most of the post-IPO period, sits ~90% below IPO projections, and the core business is still shrinking (TTM KRW 5.2 bn).

  2. The 2026 financing pattern resembles a control-transfer/M&A vehicle more than an operating turnaround. Earmarking ~KRW 11.5 bn (plus a KRW 10 bn C&P issue) for undisclosed "other companies' securities", after-hours change-of-control disclosure, and an above-market C&P subscription raise the risk that capital is deployed outside the NGS core.

  3. Valuation already discounts success. At ~21x TTM sales and 3.6x book after a ~255% YTD rally, the market capitalization (~KRW 110 bn) is ~11x the entire three-year Achieve minimum; with no coverage and low liquidity, downside on any Achieve under-performance or failed C&P funding could be severe.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it mattersExpected timing
First Achieve kit orders and royalty recognitionProof of contract performanceQ4 2026 – Q1 2027 results
Q3 2026 quarterly reportRevenue trajectory; CB/derivative accounting; cash positionMid-Nov 2026
Completion or cancellation of KRW 10 bn C&P issueFunding certainty; signal on M&A plansPending
Disclosure of "other companies' securities" acquisitionsDetermines whether capital stays in NGS or diversifiesCompany said "sequentially"
MCPTX MOU conversion to a definitive agreementPayer-side volume2026–2027
KDCA contract renewal beyond 2026Domestic base revenueLate 2026 / early 2027
FY2026 business report: pre-tax loss vs. equity, revenue vs. listing thresholdsKOSDAQ listing-maintenance complianceMar 2027
IMBdx share priceDrives FVTPL gains/lossesContinuous
CB conversion / put datesDilution or cash outflowTerms not disclosed
India subsidiary growth; CancerMaster adoptionDiversification of growth2026–2027

Analyst verdict

Celemics is a genuine technology company trapped inside a sub-scale business. Its founders built a rare capability — independent manufacture of hybrid-capture probe pools with good uniformity and molecular-barcoding chemistry — that very few companies outside the US and China possess. Yet six years after a heavily oversubscribed IPO, the company has never earned an operating profit, its revenue is lower than in 2021, and it delivered roughly a tenth of what it promised investors at listing. Its single profitable year was an accounting gain on someone else's IPO.

2026 changed the shape of the story rather than its substance. The Achieve Diagnostics agreement is the most important commercial event in the company's history: it is structured intelligently, with minimum commitments, a 20% royalty on reimbursed US tests and an exclusivity-termination remedy, and its minimums alone are material relative to Celemics' revenue. If it performs, Celemics moves from selling research reagents to participating in clinical test economics — the right strategic direction for an independent probe maker. CancerMaster's low-cost positioning gives the platform a second credible wedge.

Against this, the governance and capital-allocation signals are mixed to negative. Control passed to a new shareholder whose background is not publicly documented, through a low-priced placement disclosed after hours on a limit-up day. A substantial share of the ~KRW 31 bn raised is earmarked for acquiring undisclosed companies, and a further KRW 10 bn issue sits at roughly twice the market price with uncertain completion. The equity has already re-rated ~3.5x year-to-date to a valuation that implies substantial over-delivery on Achieve.

Verdict: technologically interesting, commercially unproven, and governance-sensitive. The investment case rests on verifiable execution — Achieve royalties appearing in Q4 2026/Q1 2027 filings and capital being deployed into NGS-adjacent assets. Until both are evidenced, Celemics should be treated as a high-risk, event-driven special situation rather than a fundamental growth holding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / role historyBackgroundSource

Park Jong-gap (박종갑)

Co-CEO (Representative Director); largest shareholder

Acquired control Feb 2026; listed as representative director on Feb 2026 filing

Prior roles and education not publicly disclosed in sources reviewed

DART filing; Edaily; KU TLO

Kim Hyo-ki (김효기)

Co-CEO (Representative Director); co-founder

Co-founder 2010; co-CEO pre-IPO to present; largest shareholder until Feb 2026

Founder; promotes company at international conferences

Dealsite 2020; Edaily 2026

Lee Yong-hoon (이용훈)

Former CEO / former co-CEO

CEO at 2020 IPO; sold shares in Feb 2026 change of control; participated in mid-2026 rights issue as "former CEO"

—

Dealsite 2020; Edaily 2026; VentureSquare 2026

Lee Sang-seok (이상석)

Director; Head of Management Support (filing officer)

In role 2026; bought shares on market 2026

—

DART filing; TheVC

Kwon Sung-hoon (권성훈)

Co-founder

—

Academic

Dealsite, 2020

Bang Doo-hee (방두희)

Co-founder

—

Academic

Dealsite, 2020

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContextSource

3 Feb 2026 (filing)

Park Jong-gap becomes largest shareholder and co-CEO; Lee Yong-hoon exits co-CEO role

Lee Yong-hoon and Kim Hyo-ki sell ~430,000 shares (5.27%) at KRW 6,000/share to Park; Park subscribes 760,746 new shares

Edaily, 11 Feb 2026

13 Jul 2026 (filing)

Outside director appointment/resignation

Details not disclosed in sources reviewed

Butler

Sep–Oct 2026

Co-CEO and executives purchase shares on market

Stated purpose: responsible management

TheVC

Major Shareholders

HolderStakeBasisSource

Park Jong-gap

≈ 1.19M shares (≈ 10.7%) — analyst estimate: 430,000 acquired + 760,746 new shares ÷ 11.18M; excludes any subsequent trades

Derived

Edaily; Google Finance

Kim Hyo-ki

Residual stake after Feb 2026 sale not disclosed

——

C&P (씨앤피)

915,000 shares (≈ 7.6% post-issue) if KRW 10 bn issue completes; completion not confirmed

Conditional

Littlebit; Bullstory

Investment partnership including a US medical-school professor ("Professor Kim", biomedical engineering; publication tag references Johns Hopkins)

Participated in mid-2026 rights issue; stake not disclosed

—

VentureSquare, Jun 2026

IMBdx-related, Partners Investment, WONIK Investment Partners

Historical investors; current holdings not disclosed

—

Dealsite 2020; CB Insights

Competitive Landscape

Key Competitors

CompetitorRelevant franchiseSegment overlapPositioning vs. Celemics

Agilent Technologies (USA)

SureSelect hybrid-capture panels and exomes

Target enrichment, exome, custom panels

Global incumbent; far larger scale and installed clinical base

Twist Bioscience (USA)

Silicon-synthesized hybrid-capture probes, exome, custom panels

Target enrichment, custom panels

Fastest-growing pure-play probe supplier; synthesis-cost leader

Integrated DNA Technologies (Danaher)

xGen hybridization capture

Target enrichment

Broad oligo franchise; strong US channel

Roche (Switzerland)

KAPA HyperCap / HyperChoice, KAPA library prep

Target enrichment, library prep

Integrated workflow vendor

Illumina (USA)

TruSight Oncology 500, enrichment kits; sequencers

CGP panels (CancerMaster comparator), enrichment

Platform owner; CancerMaster priced at a stated 1/3–1/4 of competing products

Thermo Fisher Scientific (USA)

Ion AmpliSeq / Oncomine (amplicon)

Oncology panels (different chemistry)

Amplicon alternative on Ion Torrent

QIAGEN (Netherlands)

QIAseq targeted panels (UMI-based)

UMI panels (BTSeq overlap)

UMI chemistry competitor

MGI Tech (China)

MGIEasy exome/capture kits; sequencers

Exome, China market

Low-cost instrument ecosystem

Pillar Biosciences (USA)

SLIMamp oncology panels

Oncology panels

Clinical kit focus

Chinese probe makers (e.g., iGeneTech, Nanodigmbio)

Hybrid-capture probes

Target enrichment in China

Price competition in China

Dxome (Korea)

DxSeq NGS panels

Korean clinical panels

Domestic panel competitor

NGeneBio (Korea)

BRCAaccuTest, oncology panels

Korean clinical panels

Domestic competitor

GC Genome / Macrogen (Korea)

Clinical and research sequencing services

NGS services

Service-side competitors (and occasional partners)

IMBdx (Korea)

AlphaLiquid liquid biopsy

Liquid biopsy

Adjacent; Celemics is a ~9.8% shareholder

Peer Comparison FY2024

CompanyFiscal yearRevenueRevenue growthNotes

Celemics

FY2025

KRW 5.8 bn (≈ USD 4.2M)

-14.2%

Operating margin -57%; R&D 18% of revenue

Illumina

FY2024

USD 4.37 bn

≈ -3%

—

Agilent Technologies

FY2024 (Oct)

USD 6.51 bn

≈ -5%

As above

Twist Bioscience

FY2024 (Sep)

USD 313M

≈ +28%

As above

Recent Developments

Note on item 6: a KIND document excerpt surfaced in search listing 2024–2026 small public offerings and a 2024 change of largest shareholder to "포퓨쳐개발" appears to belong to a different issuer (its fiscal-period numbering and shareholder history do not match Celemics). These items have therefore been excluded* from Celemics' history and are noted here only for transparency.

Company Snapshot

$4.1M

Revenue

40

Employees

$80M

Market Cap

2010

Founded

SWOT Analysis

Strengths

  • Rare manufacturing capability: IPO prospectus claimed only six companies worldwide could commercialize target capture kits, Celemics being the only one in Europe/Asia/Middle East (Biospectator, Aug 2020; Dealsite, Oct 2025).
  • Proprietary platforms: MSSIC cloning and BTSeq UMI chemistry with sub-1% VAF sensitivity (KU TLO).
  • First royalty-bearing US clinical contract: min. USD 7.225M over three years, equal to 172% of FY2025 revenue (Hankyung, 1 Sep 2026).
  • Favourable contract protections: shortfall payments/kit purchases and Celemics' right to convert exclusivity to non-exclusive if minimums are missed (MoneyToday; Hankyung).
  • Recapitalized balance sheet: ~KRW 31 bn raised in H1 2026 versus FY2025 operating loss of KRW 3.3 bn (VentureSquare).
  • Public-sector credibility: KDCA 2025–2026 surveillance contract; COVID-19 genome delivered to KCDC within one day in February 2020 (KU TLO; Biospectator).
  • Low-cost CGP offering: CancerMaster 524 genes at a claimed 1/3–1/4 of competitor cost, with a Yonsei clinical study (Sat Economy, 2026).

Weaknesses

  • Never operationally profitable since listing; operating losses KRW 1.9–6.0 bn every year FY2021–FY2025 (Dealsite; Butler).
  • Shrinking revenue: FY2025 KRW 5.8 bn vs. FY2022 peak KRW 8.7 bn; TTM Jun-2026 KRW 5.2 bn (ValueLine).
  • IPO-target credibility gap: 2024 revenue ~90% below IPO-era projection (Dealsite, 24 Oct 2025).
  • Low gross margin for a reagent business: 49.7% FY2025, ~43% TTM (ValueLine).
  • Earnings hostage to an equity stake: FY2024 profit entirely from IMBdx revaluation; TTM financial losses KRW 6.3 bn (Dealsite; ValueLine).
  • Thin organization: ~40–47 employees (Google Finance; TheVC).
  • Governance perception: after-hours disclosure of control change on a limit-up day, with no response to press inquiries (Edaily, Feb 2026).

Opportunities

  • Achieve upside above minimums: royalties scale with test volume; ~172 tests/month at USD 2,000 net covers the minimum net-sales commitment (MoneyToday).
  • Payer partnership: MCPTX MOU could channel Medicare Advantage volume (CB Insights / EIN, Jul 2026).
  • Panel expansion in the US: company intends to add cancer types, liquid biopsy and companion diagnostics (Hankyung).
  • India growth: subsidiary reached ~KRW 0.5 bn in year one (KU TLO).
  • M&A with ~KRW 11.5–21.5 bn earmarked for acquiring other companies' securities (VentureSquare; C&P issue).
  • Pathogen surveillance: continuation of KDCA program beyond 2026; H5N1 sequencing interest (LinkedIn).

Threats

  • Single-counterparty concentration: Achieve had no prior NGS testing capability before this deal (MoneyToday).
  • Dilution: share count up ~37% from 8.16M to ~11.18M in 2026; C&P issue and CB conversion could add more (DART; Google Finance).
  • Overhang of above-market C&P subscription at KRW 19,233 vs. KRW 9,640 market price — risk of non-completion or renegotiation (Littlebit; ValueLine).
  • Competition from scaled probe suppliers (Twist ≈ USD 313M revenue FY2024) and Chinese price competition.
  • KOSDAQ listing-maintenance rules for loss-making, special-track companies once exemptions lapse (rules described in Dailypharm/Hankyung coverage of other issuers).
  • Macro / market risk: 15 Oct 2026 Korean market sell-off; stock is highly volatile (52-week range KRW 2,535–19,840).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19–26 May 2025Participates in ValueFinder May Corporation Day (IR event) IRGOInvestor outreach
Jun 2025Exhibits at ASM Microbe 2025, Los Angeles (Booth #1237) LinkedInUS microbiology market push
2025Exhibits at ACMG 2025, FoG Boston, ASHG 2025 LinkedInUS clinical genetics visibility
2025AMO Lifescience cfDNA isolation kit partnership; free CeleMag bead samples for US validation LinkedInWorkflow and channel building
2025KDCA 2025–2026 surveillance supply contract KU TLOPublic reference revenue
18 Aug 2025 (aggregator-listed; attribution uncertain)Small public offering rights issue (~KRW 1.0 bn) KIND excerpt (see note)Funding (see note)
23–27 Oct 2025Press analysis: revenue 90% below IPO targets; IMBdx valuation swings DealsiteCredibility pressure
30 Jun 2025 (reported Oct 2025)H1 2025: revenue KRW 2.8 bn (-14.7%), operating loss KRW 1.8 bn, net loss KRW 5.1 bn DealsiteContinued decline
–FY2025 results: revenue KRW 5.8 bn (-14.2%), operating loss KRW 3.3 bn, net loss KRW 4.0 bn ButlerLosses widen
3 Feb 2026Shares limit-up; after-close disclosure of change of control, KRW 4.29 bn rights issue, KRW 5 bn CB EdailyControl transfer
3 Feb 2026Lee Yong-hoon and Kim Hyo-ki sell ~430,000 shares at KRW 6,000 to Park Jong-gap EdailyFounder/management exit from control
H1 2026Further third-party rights issue (~KRW 11.6 bn) and CBs Asia Economy headlines; VentureSquareRecapitalization
30 Apr / 4 May 2026IR presentation: company introduction and business status IRGOPost-control-change narrative
12 May 2026Correction filing: new-share listing date moved from 15 May to 4 Jun 2026 DART via Seoul Economic DailyAdministrative delay
28 May – 12 Jun 2026—
4 Jun 2026Feb 2026 new shares listed DART correctionShare count rises to ~9.8M
8 Jun 2026Announces completion of ~KRW 12 bn rights issue; total ~KRW 31 bn raised; ~KRW 11.5 bn for other-company securities; US medical-school professor's partnership and former CEO participate VentureSquareGrowth-capital narrative
13 Jul 2026Outside director change filing ButlerBoard change
14 & 16 Jul 2026Executive/major shareholder ownership reports ButlerInsider activity
20 Jul 2026MCPTX MOU (Texas Medicare health plan) CB Insights / EINUS payer access
21 Jul 2026Large-holding (5%) report filed ButlerOwnership change
c. 24 Jul 2026KRW 10 bn third-party issue to C&P at KRW 19,233 Bullstory; LittlebitM&A war chest; aggregator flagged as strongly negative
14 Aug 2026Half-year report filed (H1 2026) Butler; analyst derivationDerived H1 revenue ~KRW 2.3 bn, large net loss
27 Aug 2026Shares +29.95% limit-up to KRW 10,890 ValueLinePre-contract price spike
1–3 Sep 2026Achieve Diagnostics license and supply agreement (min. USD 7.225M / ≈ KRW 9.92 bn, 172% of FY2025 revenue) Hankyung; MoneyTodayLargest commercial agreement in company history
Before 4 Sep 2026Director Lee Sang-seok buys shares on market TheVCInsider confidence signal
Sep–Oct 2026Co-CEO and executives buy shares TheVCInsider confidence signal
2026CancerMaster study by Yonsei researchers publicized Sat EconomyClinical validation claim
15 Oct 2026Korean equity sell-off (KOSPI/KOSDAQ sell sidecars triggered); Celemics closes KRW 9,640 MoneyToday; ValueLineMacro headwind

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total revenue fell from KRW 8,100 Mn in FY2021 to KRW 5,800 Mn in FY2025.
Celemics, Inc. — Revenue by Segment
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Total revenue8,1008,7006,6006,7005,800

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DART/KOSCOM major-matters report (rights issue, 3 Feb 2026; correction 12 May 2026) via Seoul Economic Daily (sedaily.com)
  2. Edaily / Pharm Edaily, "상한가 먼저, 공시는 밤에…셀레믹스, 최대주주 변경" (Feb 2026) (v.daum.net)
  3. Hankyung, Achieve Diagnostics agreement (1 Sep 2026) (hankyung.com)
  4. MoneyToday, "3년 최소 99억 확보" (4 Sep 2026) (mt.co.kr)
  5. VentureSquare, KRW 31 bn fundraising (8 Jun 2026) (venturesquare.net)
  6. Dealsite, IPO-target gap (24 Oct 2025) (dealsite.co.kr)
  7. Dealsite, IMBdx valuation effects (27 Oct 2025) (dealsite.co.kr)
  8. Dealsite, Partners Investment / founders (6 Apr 2020) (dealsite.co.kr)
  9. Dealsite, IPO press conference (30 Jul 2020) (dealsite.co.kr)
  10. Dealsite, IPO valuation revision (28 Jul 2020) (dealsite.co.kr)
  11. Dealsite, growth-track listings (2 Sep 2020) (dealsite.co.kr)
  12. Biospectator, IPO subscription results (Aug 2020) (biospectator.com)
  13. Biospectator, preliminary listing approval (Jun 2020) (biospectator.com)
  14. Biospectator, technology evaluation and MEDLAB 2020 (biospectator.com)
  15. Biospectator, registration statement filing (biospectator.com)
  16. Biospectator, SNU Hospital co-development / China ICL (biospectator.com)
  17. Dailypharm, KRW 4.5 bn China contract (2 Jul 2021) (m.dailypharm.com)
  18. MTN, Shinhan Investment initiation (24 Aug 2020) (news.mtn.co.kr)
  19. Daishin Securities IPO-manager reports (Dec 2020, Jun 2021) · file.alphasquare.co.kr
  20. Asia Economy, limit-up and business description (Aug 2024) (view.asiae.co.kr)
  21. Sat Economy, CancerMaster study (2026) (sateconomy.co.kr)
  22. Korea University TLO partner profile (tlo.korea.ac.kr)
  23. ValueLine financial data (accessed 16 Oct 2026) (valueline.co.kr)
  24. Butler company page (butler.works)
  25. Google Finance quote (google.com)
  26. StockHub (stockhub.kr)
  27. Investing.com (kr.investing.com)
  28. Littlebit (mydailybyte) (mydailybyte.com)
  29. Bullstory, C&P rights issue (bullstory.io)
  30. TheVC company profile (thevc.kr)
  31. Bizwatch, special-listing biotech control changes (Oct 2026) (news.bizwatch.co.kr)
  32. CB Insights (MCPTX MOU summary) (cbinsights.com)
  33. GenomeWeb, US subsidiary launch (genomeweb.com)
  34. Simply Wall St (simplywall.st)
  35. EMIS company profile (emis.cn)
  36. Medical-XPRT product pages · medical-xprt.com
  37. Funakoshi distributor brochure (funakoshi.co.jp)
  38. BiopharmIQ (app.biopharmiq.com)
  39. Justia Trademarks · trademarks.justia.com
  40. LinkedIn (Kim Hyo-ki public activity) (kr.linkedin.com)
  41. IRGO IR page (m.irgo.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.